

Biofilm Production And Antifungal Resistance Among Candida Species In Patients With Vulvovaginitis: A Cross Sectional Study

Aastha Garg*, Dr. Narinder Kaur**

*Intern, **Professor & Head, Department Of Microbiology, MMIMSR, Mullana, Ambala, Haryana - 133207

Abstract: Background: Vulvovaginal candidiasis (VVC), one of the commonest fungal infections in women of reproductive age group, can become recurrent if not managed appropriately. Recently, production of biofilm, which reduces the susceptibility to anti-fungal agents, has also been implicated in its pathogenesis. Hence, the study was planned to determine the prevalence of VVC in cases of vulvovaginitis, identify the pre-dominant candida species, and find out their antifungal susceptibility pattern and to detect biofilm production in the candida isolates. Material And Methods: In this cross-sectional study, all isolates were identified and confirmed by various basic microbiological methods followed by the VITEK-2 system. Biofilm formation was detected by Congo red agar method and Tube method. Descriptive statistical methods were used to evaluate the data collected. Result: Out of total 25 patients, 7 were positive with VVC out of which 2 cases were caused by C.albicans and 5 by Candida Non Albicans (3 by C.glabrata and 2 by C.tropicalis). As compared to NAC, C. albicans is still partially sensitive to fluconazole. Fortunately, both C. albicans and C. tropicalis are still 100% sensitive to voriconazole although resistance has developed partially in C. glabrata. Biofilm production was observed in 3 cases. Conclusion: Majority of cases of VVC were due to NAC predominantly C. glabrata which has grave therapeutic implications as they show decreased susceptibility to all antifungals. Voriconazole is still effective but needs to be used rationally to avoid developing resistance to it also. The evidence of biofilm production could be an important contributor towards increased incidence of antifungal drug resistance. [Garg A Natl J Integr Res Med, 2024; 15(1): 19-25, Published on Dated: 26/01/2024]

Key Words: Antifungal Susceptibility Pattern, Biofilm, Candida Species, Vulvovaginal Candidiasis

Author for correspondence: Aastha Garg, Hostel Number 6, Maharishi Markandeshwar University, Mullana, Ambala, Haryana, Pin Code: 133207 E-Mail: aasthagarg11.ag@gmail.com Mobile: 9814822621

Introduction: Over the last few years, mycotic infections have posed a surprisingly substantial, yet unrecognized, health burden on the global population. Candida species, though commensals, can be opportunistic and initiate infections in both immunocompetent and immunocompromised individuals but higher incidence in the latter¹.

Vulvovaginal candidiasis (VVC) is one of the commonest fungal reproductive tract infections especially in women of childbearing age.

Around 75% of women experience at least one episode of VVC during their reproductive years².

Recurrent VVC [>3 episodes per year due to treatment failure] hampers the quality of life of women and can cause serious health complications.

Earlier, Candida albicans was the causative agent in majority of cases; however, episodes due to nonalbicans candida species appear to be increasing³.

The patient usually presents with symptoms such as intense vulval itching/irritation often accompanied by curdy-white discharge.

The transformation of Candida spp. from commensal to pathogen is enabled by expression of various virulence factors such as germ tube formation, adhesions, hydrolytic enzymes and formation of a biofilm⁴.

Biofilms are found to be involved in an estimate of 80% infections of the human body. They are ubiquitous in nature and are embedded in the extracellular matrix.

The presence of biofilms is of foremost medical significance as they provide the properties of better adhesion, resistance to clearance by the host immune system and decreased susceptibility to therapy⁵.

Antifungal agents commonly used to treat VVC include azoles (clotrimazole, ketoconazole, fluconazole, voriconazole) amphotericin B, nystatin, capsosungin and micafungin^{6,7}.

This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for any purpose, even commercially, provided the original work is properly cited and states its license.

Apart from adverse drug reactions and cost factors, a major limitation with long term use of antifungals is the development of drug resistant strains especially to azoles^{8,9}.

The ability of Candida to develop drug-resistant biofilms plays a crucial role in their pathogenicity.

Identification of Candida species and their antifungal susceptibility testing are necessary for optimal treatment of these infections, especially in settings where diagnosis is based on syndromic approach.

Hence, the study was planned to determine the prevalence of VVC in clinically suspected cases of vulvovaginitis and to find out the associated risk factors.

It was also planned to identify the pre-dominant candida species, find out their antifungal susceptibility pattern and to detect biofilm production in the candida isolates.

This study aims to raise awareness amongst various stakeholders namely clinicians, patients and microbiologists regarding the emerging local resistance pattern of antifungal drugs prescribed for VVC and the role of biofilm in its pathogenesis.

Material & Methods: This cross sectional, analytical study was performed on clinically suspected cases of Vulvovaginitis consulting the gynaecology department of a tertiary care hospital.

Study Site: The study was conducted in the Department of Microbiology of a tertiary care Medical College and Hospital in the rural area of North India.

Ethical clearance was obtained from the Institutional Ethics Committee before starting the study. Written informed consent was taken from each participant of the study.

Study Period: The study was performed over a period of two months (July and August, 2021).

Sample Size: It was conducted in clinically suspected cases of VVC attending the gynaecology department over the span of two months. The detailed history of each patient was taken in a semi structured proforma.

Inclusion Criteria: Clinically suspected cases of Vulvovaginitis in females of all age groups.

Exclusion Criteria: Cases other than Vulvovaginitis.

Study Tool: Samples of high vaginal swabs were collected with the help of a gynaecologist under aseptic conditions. The specimen was immediately transported in a sterile tube containing normal saline to the microbiology lab for analysis.

Data Collection: The high vaginal swab was subjected to KOH examination, Gram staining and culture on Sabouraud's dextrose agar (SDA) with Chloramphenicol. SDA slants were incubated at 37 °C for 7 days. The colonies suggestive of Candida species were further identified and confirmed by Gram staining, Germ tube test, Chlamyospore formation and colour production on CHROM agar.

Antifungal susceptibility was tested by VITEK automated system-2 using AST YSOR cards. Biofilm formation was detected by Congo red agar method and Tube method

Data Analysis: Descriptive statistical methods were used to evaluate the data collected.

Results: Out of total 25 patients, who were included in the study, 7 (28%) reported positive with vulvovaginal candidiasis. Out of the total 7 positive cases, 5 cases (71.4%) were caused by Candida Non Albicans (3 by C.glabrata and 2 by C.tropicalis). C.albicans was responsible for infection in 2 (28.6%) cases. Majority of cases (71.4%) belonged to the age group of 21-30 years and the remaining 28.6% were in the age group of 31-40 years. Mean age was 25 years with standard deviation (SD) \pm 5.41.

Out of the total cases, 6 (85.7%) were homemakers whereas only one case (14.3%) was employed as a clerk. All the cases presented with symptom of vaginal discharge which was thick curdy white in 5 cases and homogenous grey white in the remaining two cases. The discharge was odourless in majority (6) cases while it was foul smelling in 1 case. Total 6 cases (85.7%) cases also complained of pruritis and dysuria.

Table 1 depicts various risk factors which were found in positive cases of VVC.


Table 1: Predisposing Risk Factors In Positive VVC Cases (N =7)

Sr. No.	Condition	Number Of Cases	Percentage Cases
1	Pregnancy	2	28.6
2	Diabetes Mellitus	1	14.3
3	History Of Antibiotic Intake	1	14.3
4	Poor Personal Hygiene	5	71.4

All the VVC cases showed budding yeast cells with pseudohyphae when tested with KOH mount followed by culture on SDA agar which demonstrated creamy white pasty colonies. Gram staining showed the presence of gram-positive budding yeast cells. Out of total 7 cases, only 2 cases showed germ tube projections (*C. albicans*) whereas the remaining 5 cases did not show any

type of projections in their germ tube (*C. nonalbicans*). Candida species identification was done by chrom agar. Out of 7 cases, 3 cases showed pink smooth colour confirming them as *C. glabrata*, 2 cases bluish colour which confirmed as *C. tropicalis* and 2 cases light green colour identifying as *C. albicans* as depicted in Figure 1.

Figure 1: Distribution Of Candida Species On Chrom Agar



The antifungal susceptibility testing was performed for three antifungals namely fluconazole, voriconazole and amphotericin B and the results are shown in Table 2. Figure 2, 3 and 4 depict the sensitivity profile of various candida

species i.e., *C. albicans*, *C. tropicalis* and *C. glabrata* to various antifungals respectively. Biofilm production was observed in 3 cases (43%) and the results are depicted in figure 5.

Table 2: Antifungal Susceptibility Testing Pattern Of Various Candida Species

Drug		FCA		VCA		Amp B	
Species	No.	S	R	S	R	S	R
<i>C. albicans</i>	2	1	1	2	0	2	0
<i>C. glabrata</i>	3	0	3	2	1	2	1
<i>C. tropicalis</i>	2	0	2	2	0	1	1

FCA = Fluconazole, VCA = Voriconazole, Amp B = Amphotericin B, S = Susceptible, R = Resistant

Figure 2: Antifungal Susceptibility Pattern In Candida Albicans




Figure 3: Antifungal Susceptibility Pattern In Candida Glabrata




Figure 4: Antifungal Susceptibility Pattern In Candida Tropicalis





Figure 5: Biofilm Production By Candida Species In VVC



Discussion: The prevalence of VVC in our study is 28% and a similar prevalence rate has been observed in many recent studies. The prevalence rate of 24% was reported by Khan et al¹⁰, 20% by Ahmed et al¹¹, 23.7% by Kalaiarasan et al¹² and 18.5% by Mohanty et al¹³. Much higher rates of around 40-50 % have also been reported in a number of studies from India^{14,15,16}.

Since VVC is more common in reproductive age group, majority of cases were in the age group of 21-30 years similar to other studies¹⁴. The findings of the present study reinforce the fact that the incidence of fungal infections are higher in the presence of various risk factors like diabetes, pregnancy, history of antibiotic intake etc.

For many years, the predominant species isolated in candidiasis was *C. albicans*. However, recently there appears to have been a trend toward a greater prevalence of non-*albicans* species (NAC) such as *C. glabrata*, *C. krusei*, *C. parapsilosis*, and *C. tropicalis* in fungal cultures. In our study, majority of cases (71.4%) were due to NAC predominantly *C. glabrata*.

A study conducted by Kombade et al at AIIMS, Jodhpur reported that more than 80% of isolates were NAC with *C. glabrata* responsible for 58% of infections followed by *C. albicans* and *C. tropicalis*¹⁴.

A study at JIPMER, Puducherry by Kalaiarasan et al reported *C. glabrata* (45.1%) to be the most common isolate followed by *C. tropicalis* (23.5% and *C. albicans* (17.6%)¹². Similarly, Mohanty et al at AIIMS, New Delhi also observed *C. Glabrata* (50.4%) to be the commonest isolate followed by *C. albicans* and *C. tropicalis*¹³. A number of other recent studies both in India (Deorukhkar et al³, Tulasidas et al¹⁷) and worldwide (Khan et al¹⁰) also share similar findings.

The emergence of NAC as a major contributor to VVC has grave therapeutic implications as these species show decreased susceptibility to all antifungals, particularly the azoles, which are generally used for the management of vaginal candidiasis.

Tulasidas et al reported high resistance to fluconazole especially by *C. glabrata* (100%)¹⁷. A number of other studies by Deorukhkar et al³, Kalaiarasan et al¹², Kombade et al¹⁴, Patel et al¹⁸

also echo similar views. In our study also, a trend towards increased resistance to antifungals is observed especially in NAC species.

As compared to NAC, *C. albicans* is still partially sensitive to fluconazole whereas both *C. tropicalis* and *C. glabrata* have developed complete resistance to fluconazole which may be due to their overuse during recent times.

Fortunately, both *C. albicans* and *C. tropicalis* are still 100% sensitive to voriconazole although resistance has developed partially in *C. glabrata*.

This implies that voriconazole is still effective but needs to be used rationally in VVC cases to avoid developing resistance to it also. Similarly, *C. albicans* is still sensitive to amphotericin B whereas NAC shows resistance partially.

The fact that ours is a tertiary care hospital in a rural area, where chronic and complicated cases are treated, could explain the high incidence of resistance to antifungals.

The patients would already have received these medicines intermittently before being referred to our hospital. This could also explain the higher prevalence of NAC in diagnosed cases.

In our study, 43% of candida species showed production of biofilm similar to the findings reported by tulasidas et al¹⁷ (44%) and Thamke et al¹⁹ (40%).

The ability to form biofilms is regarded as one of the most powerful pathogenic characteristics, leading to treatment failure and the recurrence of infections²⁰.

The major limitation of our study is relatively less sample size probably due to the limited span of data collection. Hence, further studies are needed with a much larger sample size to get more robust results in Indian scenario.

Conclusion: The prevalence of Vulvovaginal candidiasis in our study is 28% with highest incidence in the age group of 21-30 years. Risk factors reported in our study for VVC includes pregnancy, diabetes, history of antibiotic intake and poor personal hygiene. A pre-dominance of NAC was observed over *C. albicans* as causative species (*C. glabrata*-42.9%, *C. tropicalis*-28.6% and *C. tropicalis*-28.6%).

High incidence of resistance towards antifungals was observed especially towards fluconazole by NAC.

Hence, voriconazole should be preferred as first line drug for the management of VVC instead of fluconazole in our setup but needs to be used judiciously.

Biofilm production was observed in 43% of candida species which could be an important contributor towards increased incidence of antifungal drug resistance.

References:

1. Vaginal candidiasis. CDC [Internet]. [Cited 2023, July 26. Available from: <https://www.cdc.gov/fungal/diseases/candidiasis/genital/>.
2. Sobel JD, Faro S, Force RW, Foxman B, Ledger WJ, Nyirjesy PR, et al.
3. Vulvovaginal candidiasis: epidemiologic, diagnostic, and therapeutic considerations. *Am J Obstet Gynecol.* 1998; 178(2):203–11.
5. Deorukhkar SC, Saini S, Mathew S. Non-albicans Candida Infection: An Emerging Threat. *Interdiscip Perspect Infect Dis.* 2014; 2014:615958. doi: 10.1155/2014/615958
6. Deorukhkar SC, Saini S, Mathew S. Virulence Factors Contributing to Pathogenicity of Candida tropicalis and Its Antifungal Susceptibility Profile. *Int J Microbiol.* 2014; 2014:456878. doi: 10.1155/2014/456878
7. Muzny CA, Schwebke JR. Biofilms: An Underappreciated Mechanism of Treatment Failure and Recurrence in Vaginal Infections. *Clin Infect Dis.* 2015 Aug 15;61(4):601-6
8. Donders G, Sziller IO, Paavonen J, Hay P, de Seta F, Bohbot JM, Kotarski J, Vives JA, Szabo B, Cepuliené R and Mendling W (2022) Management of recurrent vulvovaginal candidosis: Narrative review of the literature and European expert panel opinion. *Front. Cell. Infect. Microbiol.* 12:934353. doi: 10.3389/fcimb.2022.934353
9. Paul Nyirjesy and others, Vulvovaginal Candidiasis: A Review of the Evidence for the 2021 Centers for Disease Control and Prevention of Sexually Transmitted Infections Treatment Guidelines, *Clinical Infectious Diseases*;74 (2):April 2022, Pages S162–S168, <https://doi.org/10.1093/cid/ciab1057>
10. Dharmik PG, Gomashe AV, Upadhyay VG. Susceptibility pattern of various azoles against Candida species causing vulvovaginal candidiasis. *J Obstet Gynaecol India.* 2013 ;63(2)
11. Bitew A, Abebaw Y. Vulvovaginal candidiasis: species distribution of Candida and their antifungal susceptibility pattern. *BMC Womens Health.* 2018 Jun 15; 18(1):94. doi: 10.1186/s12905-018-0607-z. PMID: 29902998; PMCID: PMC6003188.
12. Khan M, Ahmed J, Gul A, Ikram A, Lalani FK. Antifungal susceptibility testing of vulvovaginal Candida species among women attending antenatal clinic in tertiary care hospitals of Peshawar. *Infect Drug Resist.* 2018 Mar 28; 11:447-456
13. Ahmad A, Khan AU. Prevalence of Candida species and potential risk factors for vulvovaginal candidiasis in Aligarh, India. *Eur J Obstet Gynecol Reprod Biol.* 2009 May;144(1):68-71
14. Kalaiarasan K, Singh R, Chaturvedula L. Fungal Profile of Vulvovaginal Candidiasis in a Tertiary Care Hospital. *J Clin Diagn Res.* 2017 Mar;11(3)
15. Mohanty S, Xess I, Hasan F, Kapil A, Mittal S, Tolosa JE. Prevalence & susceptibility to fluconazole of Candida species causing vulvovaginitis. *Indian J Med Res.* 2007 Sep;126(3):216-9
16. Kombade SP, Abhishek KS, Mittal P, Sharma C, Singh P, Nag VL. Antifungal profile of vulvovaginal candidiasis in sexually active females from a tertiary care hospital of Western Rajasthan. *J Family Med Prim Care.* 2021 Jan;10(1):398-402
17. Samal R, Vaithy A, Kotasthane DS, Ghose S. Prevalence and clinico-mycological profile of vulvovaginal candidiasis in a tertiary care hospital. *Int J Reprod Contracept Obstet Gynecol* 2015;4:1142-7
18. Babin D, Kotigadde S, Rao PS, Rao TV. Clinico-mycological profile of vaginal candidiasis in a tertiary care hospital in Kerala. *Int J Res Biol Sci* 2013;3:55-9
19. Tulasidas S, Rao P, Bhat S, Manipura R. A study on biofilm production and antifungal drug resistance among Candida species from vulvovaginal and bloodstream infections. *Infect Drug Resist.* 2018 Nov 23;11:2443-2448
20. Patel, Lata et al. Prevalence of Candida Infection and its Antifungal Susceptibility Pattern in Tertiary Care Hospital, Ahmedabad. *Nat J Med Res* (2012): 439-441
21. Thamke, Dipak & Tayade, H & Tayade, Surekha & Bankar, Nandkishore & Rathod,

Nitin. Biofilm formation among Candida albicans isolated from vagina. International Journal of Biomedical and Advance Research 2014 5. 627-630.

22. Auler ME, Morreira D, Rodrigues FF, Abr Ao MS, Margarido PF, Matsumoto FE, Silva EG, Silva BC, Schneider RP, Paula CR. Biofilm formation on intrauterine devices in patients with recurrent vulvovaginal candidiasis. Med Mycol. 2010 Feb;48(1):211-6

Conflict of interest: None
Funding: None
Cite this Article as: Garg A, Kaur N. Biofilm Production And Antifungal Resistance Among Candida Species In Patients With Vulvovaginitis: A Cross Sectional Study. Natl J Integr Res Med 2024; Vol.15(1): 19-25